Radio Free Wall Street

What Threats Do We Really Face

I find it amazing with the world facing massive inflation, hyper inflation in third world shit holes, a raging war in Europe that’s expanding and the world on the brink of recession, they want you to worry about Gore’s Inconvenient Untruth. We’ll elucidate this foolishness in this next edition of Radio Free Wall Street.

SARS-CoV2 Spike Protein Causes Heart Damage

The SARS-CoV-2 virus that results in COVID-19 has been found to damage multiple organs beyond the lung. Interestingly, the SARS-CoV-2 spike (S) protein can be found circulating in the blood of COVID-19 patients. Experimental findings are demonstrating that the circulating S protein can bind to receptors resulting in inflammation and cell, tissue, and organ damage. Avolio et al. previously determined that the S protein acting through the cluster of differentiation 147 (CD147) receptor, and another unknown mechanism had detrimental effects on human cardiac pericytes (Clin Sci (Lond) (2021) 135 (24): 2667-2689. DOI: 10.1042/CS20210735). These findings support the notion that circulating SARS-CoV-2 S protein could contribute to cardiovascular disease independent of viral infection. Future studies are needed to determine the effect of the S protein on pericytes in other organs and evaluate the effectiveness of CD147 receptor-blocking therapies to decrease organ damage caused by the S protein. NN: We are seeing heart complications in people who have been infected with COVID 19. See the study from a credible source in PubMed below:

COVID-19 microvascularcs-2021-0735

Radio Free Wall Street

Cooperate or Perish

The UN Chief warned us “Humanity has a choice. Cooperate or perish.” “It is either a climate solidarity pact or a collective suicide pact.” “The world is on a highway to climate hell.” I accept their ultimatum and I’ll take my chances and see whether or not I perish. We cover the climate change absurdity in this edition of Radio Free Wall Street.

Hospitalizations on the rise in New York City as new COVID strains spread rapidly

Hospitalizations are rising again in New York City with the spread of new COVID-19 subvariants that are better at evading immunity. Cases of flu and respiratory syncytial virus, or RSV, are also increasing. State data show about 1,100 patients hospitalized with COVID as of Oct. 24, up from 750 in mid-September, as the New York Times reported. Case numbers have held steady, although with many people testing at home where data are not being collected, those numbers are not reliable. Data from the Centers for Disease Control and Prevention show that the omicron sublineages named BQ.1 and BQ.1.1 accounted for 42.5% of all cases in the New York region in the week through Oct. 29, up from 37% the previous week. That was more than the BA.5 omicron subvariant, which accounted for 35.7% of new cases in the New York region in the latest week. The two sublineages were not even registering as recently as three weeks ago, demonstrating just how fast they are spreading. Experts are also concerned about a nationwide surge in RSV, which can cause breathing difficulties in small children and older adults and for which there is currently no vaccine. There was good news from Pfizer Inc., however, which said Tuesday that data from a late-stage trial of an RSV vaccine had proved effective in preventing severe illness in children up to 6 months old. The Phase 3 trial found that the vaccine, given to pregnant mothers, achieved vaccine efficacy of 81.8% in infants from birth through the first 90 days of life. The trial found efficacy of 69.4% through the first 6 months of life. Pfizer PFE, 3.13% said it expects to make its first U.S. regulatory application for the vaccine by the end of 2022 and to follow on with other regulatory bodies. It will also submit the results of the trial for peer review in a scientific journal. The daily U.S. average for new COVID cases stood at 37,665 on Monday, according to a New York Times tracker, which was flat as compared with two weeks ago. The daily average for hospitalizations was up 2% to 27,184, while the daily average for deaths was down 3% to 348.  NN: Do not be lulled to sleep. There is the sound of breaking glass coming from the back porch. Time to break out the hammer (lefties do not have guns) because no one is watching the video cameras…. I get my 5th shot next week…

Sometimes I wonder about things. Here is a picture of the back porch where the “right wing MAGA conservative crazy” broke in

U.S. House Speaker Pelosi's husband violently assaulted during break-in at their house in San Francisco

You can see where the lower right window is missing. I was wondering if it was a break IN why is the broken glass and debris on the outside?

New COVID strains more deadly

The new COVID-19 subvariants that are becoming dominant all over the world aren’t just more contagious than previous variants and subvariants—they might cause more severe disease, too. That’s an ominous sign if, as experts predict, there’s a new global wave of COVID in the coming months. It’s one thing to weather a surge in infections that mostly results in mild disease. Cases go up but hospitalizations and deaths don’t. But a surge in serious disease could lead to a surge in hospitalizations and deaths, too. It could be like 2020 or 2021, all over again. The big difference is that we now have easy access to safe and effective vaccines. And the vaccines still work, even against the new subvariants. A new study from The Ohio State University is the first red flag. A team led by Shan-Lu Liu, co-director of HSU’s Viruses and Emerging Pathogens Program, modeled new SARS-CoV-2 subvariants including BQ.1 and its close cousin, BQ.1.1.

The team confirmed what we already knew: BQ.1 and other new subvariants, most of them the offspring of the BA.4 and BA.5 forms of the Omicron variant, are highly contagious. And the same mutations that make them so transmissible also make them unrecognizable to the antibodies produced by monoclonal therapies, rendering those therapies useless.

That should be reason enough to pay close attention as BQ.1 and its cousins outcompete BA.4 and BA.5 and become dominant in more countries and states. But then Liu and his teammates also checked the subvariants’ “fusogenicity.” That is, how well they fuse to our own cells. “Fusion between viral and cellular membrane is an important step of viral entry,” Liu told The Daily Beast. In general, the greater the fusogenicity, the more severe the disease. Liu and his colleagues “observed increased cell-cell fusion in several new Omicron subvariants compared to their respective parental subvariants,” they wrote in their study, which appeared online on Oct. 20 and is still under peer review at New England Journal of Medicine. If these new subvariants are indeed more transmissible and more severe, they could reverse an important trend as the COVID pandemic grinds toward its fourth year. The trend, so far, has for each successive major variant or subvariant to be more contagious but cause less severe disease. That trend, combined with widespread vaccination and new therapies, led to what scientists call a “decoupling” of infections and deaths. COVID cases occasionally spike as some new, highly-contagious new variant or subvariant becomes dominant. But because these new forms of SARS-CoV-2 cause less severe disease, deaths don’t increase nearly as much. That decoupling, along with the availability of vaccines and therapies, has allowed most people all over the world to get back to some kind of normal in the past year or so. If BQ.1 or another highly fusogenic subvariant re-couples infections and deaths, that new normal could become a new nightmare. “More hospitalizations and deaths,” is how Ali Mokdad, a professor of health metrics sciences at the University of Washington Institute for Health who was not involved in the OSU study, summed it up. It’s possible we’ve already seen the first recoupling. Since the new subvariants began seriously competing for dominance in recent months, epidemiologists watched COVID statistics carefully in order to spot any real-world impacts.  For all their transmissibility and fusogenicity, the new subvariants haven’t significantly escaped the immune effects of the leading vaccines. And the latest “bivalent” boosters, formulated specifically for BA.4 and BA.5, should maintain the vaccines’ effectiveness as long as the dominant subvariants are closely related to Omicron. Get vaccinated and stay current on your boosters. It’s impossible to stress this too much. Yes, BQ.1 and its cousins exhibit some alarming qualities that could bend the arc of the pandemic back toward widespread death and disruption. NN: I was hoping I would not have to publish another COVID warning. Time to get your booster shot.

Radio Free Wall Street

Energy Bills Are the Least of Their Problems

While the world is following the intrigue in Ukraine and the manipulations in oil, another event that could lead to a Lehman moment is happening and that is the collapse of the global bond market and that is because of tricky instruments that allow mutual funds and retirement funds to leverage their bond portfolio. Which means move over tent city as they become the fastest growing real estate in the world.

Radio Free Wall Street

Putin Knows How to Play a Weak Hand

As Europe walked into the free cheese at the center of the Russian food and energy mouse trap, Putin has leveraged his position with extraordinary precision. With the whole free world lined up against him, Putin is now playing his nuclear wild card. Do not make the mistake of misunderstanding how serious he is. Having been a professional trader for most all of my adult life, you learn very quickly how to run from a bad trade. It is astonishing to me the grave mistakes the democracies with their joke leaders are making. We cover all of this in our latest offering of Radio Free Wall Street.

Radio Free Wall Street

It’s Time to Warn People What’s Coming

Radio Free Wall Street has a long tradition of warning anyone smart enough to listen of the last market disasters of the last 20 years. The tech wreck, 9/11 market crash and the 2007-08 financial crisis immediately come to mind. The warning today will be bigger than all 3 of those events combined.

S. Korea’s COVID-19 tally above 100,000 for 5th day in a row……. bark Bark

SEOUL, Aug. 4 (Yonhap) — South Korea’s new COVID-19 cases stayed above 100,000 for the third straight day Thursday amid a fresh wave of infections driven by a highly infectious omicron variant. The country added 107,894 new COVID-19 infections, including 435 from overseas, bringing the total caseload to 20,160,154, the Korea Disease Control and Prevention Agency (KDCA) said. Thursday’s figure fell from the 119,922 the previous day, which was the highest since the 125,822 cases reported April 15. The daily caseload was 1.22-times higher than the 88,374 reported a week ago and 1.52-times more than the 71,142 cases from two weeks ago on the spread of the now-dominant omicron variant BA.5. Health authorities warned people to take precautions as the number of seriously ill patients rose to 310, the highest figure since May 18, when the tally stood at 313. The KDCA reported 34 deaths from COVID-19, raising the death toll to 25,144. The fatality rate was 0.13 percent. Among the 172 deaths reported from July 24-30, 167, or 97.1 percent, are aged over 50. Of the 167 people, 61, or 36.5 percent, were either unvaccinated or had received only one shot, the KDCA said. NN: this does not look good for the coming US and European Covid season starting this fall…

Moderna and Pfizer to start clinical trials for COVID-19 boosters that target the deadly BA.5 ‘in the near future’

We need vaccines with longer duration and greater breadth of protection,’ said Dr. David Kessler, chief science officer for the White House’s COVID-19 response team

Moderna MRNA, 2.82% and Pfizer PFE, -0.62% have not yet started clinical trials for the new COVID-19 shots that are expected to better target the BA.4 and BA.5 strains of the virus.  It has long been expected that the COVID-19 vaccines need to be reformulated to better protect against currently circulating variants. The Food and Drug Administration in June recommended that the next generation of COVID-19 boosters use a “bivalent” approach that equally targets the original version of SARS-CoV-2 and the BA.4/5 strains of the virus. Pfizer plans to start the clinical trial for the BA.4/5-containing vaccine it’s developing with BioNTech BNTX, -1.07% “in the near future,” a company spokesperson announced this week. The submission to the FDA for these shots will be slightly different in order to speed up their availability, according to Dr. Mikael Dolsten, Pfizer’s chief scientific officer, based on a FactSet transcript of Thursday’s earnings call. He told investors that Pfizer and the FDA have agreed that the application for the updated booster will include “safety and immunogenicity data generated in adults with an omicron-modified BA.1 vaccine and supported by BA.4/5 bivalent-specific preclinical data and BA.4/5 bivalent chemistry, manufacturing and controls data.” The drug maker this week announced the launch of a Phase 2 trial studying COVID-19 vaccines that include either a BA.1 or a BA.2 component. Moderna also has a bivalent booster targeting BA.1 in development and is planning to soon launch a clinical trial for a booster that includes BA.4/5.  “We are discussing the trial details with the FDA,” the Moderna spokesperson said in an email. “The trial will be structured similarly to other variant-of-concern studies.” BA.5, which is now the most dominant strain of the virus in circulation, is the most transmissible form of SARS-CoV-2 so far. It’s driving the surge in new cases — the U.S. is averaging about 127,000 new cases every day — and the omicron subvariant is also behind the uptick in hospitalizations. There are about 43,000 people in the hospital right now who have tested positive for the virus.  “This virus has continued to prove more than a formidable foe, with variants of concerns emerging, each with a bit of enhanced transmissibility,” Dr. Anthony Fauci, the president’s chief medical adviser, said earlier this week during a White House summit. “How do we know that? It keeps bumping off the prior variants, as we’re starting to see now with the highly transmissible BA.5. Now, innovative approaches are clearly needed to induce broad and durable protection against coronaviruses, known and unknown.”
Continue reading “Moderna and Pfizer to start clinical trials for COVID-19 boosters that target the deadly BA.5 ‘in the near future’”